Recent Quotes
My Watchlist
Indicators
Silicon Valley 150
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Summit Therapeutics Inc. - Common Stock (NQ:SMMT)

20.04 -0.95 (-4.55%)
Official Closing Price Updated: 4:15 PM EDT, Oct 20, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 9,375,373
Open 18.85
Bid (Size) 19.98 (1)
Ask (Size) 20.04 (5)
Prev. Close 20.99
Today's Range 18.08 - 20.98
52wk Range 15.55 - 36.91
Shares Outstanding 97,381,774
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
What's Going On With Summit Therapeutics Stock On Monday?
Summit Therapeutics shares Phase 3 data showing ivonescimab cut cancer progression risk by 40% and plans BLA submission in late 2025. 
Via Benzinga
Retail Investors' Top Stocks With Earnings This Week: Tesla, Netflix, Intel and More
Retail investors prepare for the first busy week in the Q3 earnings season, with Tesla, Netflix and Intel on deck. 
Via Benzinga

Performance

YTD
+9.2%
+9.2%
1 Month
+4.9%
+4.9%
3 Month
-23.9%
-23.9%
6 Month
-20.6%
-20.6%
1 Year
-2.3%
-2.3%

More News

Read More
Summit Therapeutics Inc (NASDAQ:SMMT) Reports Wider-Than-Expected Q3 2025 Loss
Via Chartmill
Summit Therapeutics Stock Sparks Retail Buzz After Ivonescimab Combo Cuts Cancer Progression Risk By 40%
Via Stocktwits
An Overview of Summit Therapeutics's Earnings
Via Benzinga
Summit Therapeutics Stock Draws Cautious Retail Mood After Barclays ‘Underweight’ Call: ‘Added To The Biotech Graveyard’
Via Stocktwits
Summit Therapeutics Reports Financial Results and Operational Progress for the Third Quarter and Nine Months Ended September 30, 2025
From Summit Therapeutics
Via Business Wire
Earnings Scheduled For October 20, 2025
Via Benzinga
Ivonescimab with Chemotherapy Reduced the Risk of Disease Progression or Death by 40% Compared to Tislelizumab (PD-1 Inhibitor) Plus Chemotherapy in 1L Treatment of Patients with Squamous NSCLC in the HARMONi-6 Study Conducted by Akeso in China
From Summit Therapeutics
Via Business Wire
Summit Therapeutics Announces Expansion of Ivonescimab Global Phase III Development Program with HARMONi-GI3 Study in 1L Colorectal Cancer
From Summit Therapeutics
Via Business Wire
Summit Therapeutics to Host ESMO Data Update & Third Quarter Earnings Call on October 20, 2025
From Summit Therapeutics
Via Business Wire
10 Health Care Stocks Whale Activity In Today's Session
Via Benzinga
1 Monster Stock in the Making to Buy and Hold
Via The Motley Fool
Alpha Buying: The 3 Stocks That Just Got This $1 Million Vote of Confidence
Via Benzinga
Intel, Marvell, Electronic Arts Are Among The Top 10 Large-Cap Gainers Last Week (Sep. 22 - Sep. 26): Are The Others In Your Portfolio?
Via Benzinga
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Summit Therapeutics Inc. - SMMT
From Pomerantz LLP
Via GlobeNewswire
Summit Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Summit Therapeutics
Via Business Wire
HARMONi-6, Featuring Ivonescimab Combined with Chemotherapy vs. Tislelizumab Plus Chemotherapy in 1L Treatment of Patients with Squamous NSCLC in China, to be Showcased in Presidential Symposium at ESMO 2025
From Summit Therapeutics
Via Business Wire
Nvidia High-Fives Palantir, Rocket Lab — On This List Of '10-Bagger' Legends
Via Benzinga
This Protagonist Therapeutics Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Wednesday
Via Benzinga
Jim Cramer: Ring The Register On This Real Estate 'Meme' Stock
Via Benzinga
Synopsys, Chewy, And The Trade Desk Are Among Top 10 Large Cap Losers Last Week (Sep. 8- Sep. 12): Are The Others In Your Portfolio?
Via Benzinga
Topics Earnings
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Summit Therapeutics Inc. - SMMT
From Pomerantz LLP
Via GlobeNewswire
China-Tied Biotechs Zai Labs, BeOne Plunge On Rumored Executive Order
Via Investor's Business Daily
Topics Government
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Summit Therapeutics Inc. - SMMT
From Pomerantz LLP
Via GlobeNewswire

Frequently Asked Questions

Is Summit Therapeutics Inc. - Common Stock publicly traded?
Yes, Summit Therapeutics Inc. - Common Stock is publicly traded.
What exchange does Summit Therapeutics Inc. - Common Stock trade on?
Summit Therapeutics Inc. - Common Stock trades on the Nasdaq Stock Market
What is the ticker symbol for Summit Therapeutics Inc. - Common Stock?
The ticker symbol for Summit Therapeutics Inc. - Common Stock is SMMT on the Nasdaq Stock Market
What is the current price of Summit Therapeutics Inc. - Common Stock?
The current price of Summit Therapeutics Inc. - Common Stock is 20.04
When was Summit Therapeutics Inc. - Common Stock last traded?
The last trade of Summit Therapeutics Inc. - Common Stock was at 10/20/25 04:15 PM ET
What is the market capitalization of Summit Therapeutics Inc. - Common Stock?
The market capitalization of Summit Therapeutics Inc. - Common Stock is 1.95B
How many shares of Summit Therapeutics Inc. - Common Stock are outstanding?
Summit Therapeutics Inc. - Common Stock has 2B shares outstanding.
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.